The climate crisis is a health crisis 1 impacting the health of people around the world. When it comes to respiratory health, air pollution represents one of the main threats to patients' overall conditions and quality of life 2.
Chiesi's mission is to improve the quality of life of people worldwide and to operate in a socially and environmentally responsible manner.
Aiming to preserve both the environment and patient choice, the Company has made significant investments in the development of a new Carbon Minimal Inhalers platform, that will reduce the carbon footprint of its pressurized metered dose inhalers (pMDI) by up to 90% 3.
Learn more on our commitment by watching the brand film sponsored by Chiesi "How redesigning inhalers could reduce their environmental impact", part of "The Climate and Us" series.
"The Climate and Us" is a series presented by the Global Climate and Health Alliance and produced for them by BBC Storyworks.
It explores the impact of climate change on human health and highlights the healthcare sector's innovative responses to mitigate the risks posed by climate change.
"At Chiesi, we strongly believe that patients should not have to shoulder the burden of environmental responsibility when considering treatment options that affect their health. That’s why we are advocating for a stronger recognition of how the climate crisis is a health crisis. Being at the forefront of developing carbon-minimal inhalers, we recognize the importance of providing patients with a range of treatment options while simultaneously alleviating the environmental impact".
Giuseppe Accogli, CEO of Chiesi Group
1 https://www.who.int/news/item/24-05-2023-wha76-strategic-roundtable-on-health-and-climate
2 Economist Impact. Cleaner air, clearer lungs, better lives: exploring the intersection of air quality, health inequalities and lung health. London: Economist Impact, 2023. Available from: https://impact.economist.com/perspectives/health/cleaner-air-clearer-lungs-better-lives
3 The new inhalers, containing a more climate-friendly propellant gas, are still in active pharmaceutical development and initial availability on the market will vary by Country and product.